Back to Resources
Market Highlights
- In Q3 2025, the ARMD/DME/RVO market saw active brand engagement across Europe through educational events, regulatory milestones, and patient support initiatives. Key themes included extended-interval dosing, biosimilar adoption, dual inhibition therapies, and real-world evidence.
- Bayer advanced Eylea 8 mg across Europe with EMA filings, extended-interval approvals, and real-world data supporting sustained efficacy. The campaign positioned Eylea as a long-acting, clinically validated leader in retinal care.
- Biogen supported Byooviz and Opuviz in France with an unbranded brochure promoting biosimilar confidence through regulatory clarity, education, and collaboration. Tools like Care+ and BiogenLinc equipped HCPs with resources for shared decision-making.
- Novartis promoted Lucentis and Beovu through patient education and HCP engagement, including anniversary campaigns and unbranded materials.
- Roche drove Vabysmo’s growth through data-backed messaging on dual inhibition, safety, and durability in nAMD, DME, and RVO. It secured national funding, launched educational platforms, and hosted major symposia across Europe.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com